10/30
04:05 pm
amrn
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
Low
Report
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
10/1
08:00 am
amrn
Amarin Announces Two Upcoming Investor Events
Medium
Report
Amarin Announces Two Upcoming Investor Events
9/19
08:00 am
amrn
Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer
Low
Report
Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer
9/10
07:45 am
amrn
Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial Officer
Low
Report
Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial Officer
9/9
07:30 am
amrn
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe
Low
Report
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe
8/22
08:30 am
amrn
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
Medium
Report
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress